Basilea Pharmaceutica AG (SWX:BSLN)

Market Cap	569.33M
Revenue (ttm)	236.21M
Net Income (ttm)	72.66M
Shares Out	12.28M
EPS (ttm)	5.47
PE Ratio	8.47
Forward PE	10.69
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,683
Average Volume	42,915
Open	46.20
Previous Close	45.80
Day's Range	46.00 - 46.75
52-Week Range	37.50 - 59.70
Beta	0.71
RSI	34.54
Earnings Date	Aug 19, 2025

About Basilea Pharmaceutica AG

Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus aureus bacteremia (SAB), and acute bacterial skin and skin structure infections (ABSSSI). The company also has a clinical-stage pipeline of anti-infectiv...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 164
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: BSLN

Financial Performance

In 2024, Basilea Pharmaceutica AG's revenue was 208.54 million, an increase of 32.30% compared to the previous year's 157.63 million. Earnings were 77.59 million, an increase of 642.45%.